8-K: Cardinal Health Exceeds Expectations in Q1, Raises Full-Year Outlook

Cardinal Health reported a 4% revenue decrease in Q1, but a 15% increase excluding a large contract expiration, leading to an increased full-year earnings outlook.

Summary

• Cardinal Health's first quarter fiscal year 2025 revenue was $52.3 billion, a 4% decrease compared to the same period last year.
• However, excluding the impact of a large customer contract expiration, revenue increased by 15%.
• GAAP operating earnings were $568 million, and GAAP diluted EPS was $1.70.
• Non-GAAP operating earnings increased by 12% to $625 million, driven by the Pharmaceutical and Specialty Solutions segment.
• Non-GAAP diluted EPS increased by 9% to $1.88.
• The company has raised its fiscal year 2025 non-GAAP EPS guidance to $7.75 to $7.90, up from $7.55 to $7.70.

Sentiment

Score: 7

Explanation: The document presents a mixed picture with a revenue decrease but strong underlying growth and increased guidance. The positive outlook and strategic moves like the ION acquisition contribute to a positive sentiment, but the revenue decrease and some segment weakness temper the overall enthusiasm.

Positives

• The Pharmaceutical and Specialty Solutions segment showed strong growth, with a 16% increase in profit.
• The company's non-GAAP earnings per share increased by 9%, indicating improved profitability.
• The company has raised its full-year earnings guidance, reflecting confidence in future performance.
• The acquisition of Integrated Oncology Network is expected to enhance the company's oncology capabilities.
• The completion of a $375 million share repurchase program is a positive sign for shareholders.
• The Global Medical Products and Distribution segment saw a 3% increase in revenue.

Negatives

• Overall revenue decreased by 4% compared to the same quarter last year.
• The Global Medical Products and Distribution segment profit decreased to $8 million, due to higher manufacturing and health and welfare costs.
• GAAP operating earnings were $568 million, which is lower than the non-GAAP figure due to various adjustments.
• The company experienced a large customer contract expiration which negatively impacted revenue.

Risks

• The company faces competitive pressures in its various lines of business.
• There are risks associated with the pricing of branded pharmaceuticals and potential legislative action.
• Ongoing audits with the IRS could lead to an increase in the effective tax rate.
• The company is subject to litigation matters, including a Department of Justice investigation.
• Events outside of the company's control, such as weather or geopolitical events, could impact demand or cause supply shortages.
• The performance of the generics program and the amount of generic deflation could impact results.
• The At-Home unit goodwill could become impaired due to changes in the long-term financial plan.

Future Outlook

The company raised its fiscal year 2025 non-GAAP EPS guidance to $7.75 to $7.90, and updated its Pharmaceutical and Specialty Solutions segment profit outlook to 4% to 6% growth, and its Global Medical Products and Distribution segment profit outlook to $140 million to $175 million.

Management Comments

• We began fiscal 2025 by delivering strong operational and financial performance, led by the Pharmaceutical and Specialty Solutions segment, said Jason Hollar, CEO of Cardinal Health.
• The strength and resiliency of our largest and most significant business continues to shine, giving us confidence to raise our fiscal 2025 enterprise guidance only a quarter into the year.
• Across the business, we remain focused on executing our plan to best serve our customers and create value for our shareholders.

Industry Context

The healthcare distribution industry is competitive, with companies like McKesson and AmerisourceBergen also vying for market share. Cardinal Health's focus on specialty solutions and acquisitions like ION are strategic moves to differentiate and grow in this landscape.

Comparison to Industry Standards

• Cardinal Health's revenue decrease of 4% is notable, but the 15% increase excluding the contract expiration shows underlying strength.
• McKesson, a major competitor, reported a 12% revenue increase in their most recent quarter, indicating a stronger overall growth trend in the sector.
• AmerisourceBergen's recent results showed a 10% revenue increase, suggesting Cardinal Health's growth is lagging behind some peers.
• The acquisition of ION for $1.1 billion is a significant move, similar to other large acquisitions in the healthcare space, such as CVS's acquisition of Aetna, which aim to expand service offerings and market reach.
• Cardinal Health's non-GAAP EPS growth of 9% is solid, but needs to be compared to peers to assess relative performance.

Legal Proceedings

• The company is subject to a Department of Justice investigation focused on potential violations of the Anti-Kickback Statute and False Claims Act.

Stakeholder Impact

• Shareholders will benefit from the increased earnings guidance and share repurchase program.
• Customers will benefit from the company's focus on improving service and expanding its offerings.
• Employees may be impacted by the company's restructuring and cost-saving initiatives.
• Suppliers may see changes in demand based on the company's performance and strategic shifts.

Next Steps

• The company will continue to execute its strategic plan.
• The acquisition of Integrated Oncology Network is expected to close.
• The new distribution center in Ohio is planned to open in spring 2025.
• The company will participate in several upcoming investor conferences.

Key Dates

Keywords

Cardinal Health, Pharmaceuticals, Specialty Solutions, Medical Products, Distribution, Earnings, Revenue, EPS, Acquisition, Share Repurchase, Healthcare, Oncology